| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.4 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.4 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.058 | 0.4 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.021 | 0.4 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.4 |